HIV prevention methods for men who travel for work
Part of Infections clinical trials.
This study tests different ways of taking HIV prevention medicine (PrEP) for men who travel for work in sub-Saharan Africa. It compares daily pills, pills only around sex, and a long-acting injectable to see which method works best and is easiest to use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older (and be able to give your consent).
- You must have been assigned male at birth.
- In the past 6 months, you must have traveled away from home for work (or to look for work) and spent at least one night away.
- You must be willing to get an HIV test and know the result.
- You must be able to attend all study visits during the study period.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at ways to help minibus drivers get tested for HIV and use long-acting injectable medicine to prevent or treat HIV. It tests combining HIV self-testing with long-acting injectables to see if it improves health outcomes for drivers.
This study is for cis-gender men who are HIV-negative and at risk for HIV. It tests a program to help you start and stay on PrEP (medication to prevent HIV).
This study tests a new injectable medication called lenacapavir to prevent HIV infection. You get to choose between different HIV prevention options, and the study will see how well the injection works for you.
This trial tests a new way to take HIV prevention medicine (PrEP) only around the time you have sex, using a pill called TAF/FTC. It aims to see if this 'on-demand' method is effective, safe, and acceptable, and could offer a more flexible option than taking a pill every day.
This trial tests a long-acting injectable HIV prevention medication (cabotegravir) as an alternative to daily pills. It may be a good fit if you are a man who has sex with men and have been taking oral PrEP consistently.
This study tests an all-in-one HIV prevention package for young men at higher risk of HIV. It combines a new long-acting PrEP (injectable HIV prevention) with mobile health support and sexually transmitted infection prevention. The goal is to see if this comprehensive approach works better than standard care.
Hear when a new HIV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.